Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least  years.
Subjects must not have had prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than  cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (as per P, A, ANBL, or similar) prior to determination of MYCN amplification status and histology.
Patients must not be at short term risk for life threatening complications (such as airway compromise or bleeding from locoregional or metastatic disease,).
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Life-threatening visceral disease or other severe concurrent disease
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Life-threatening visceral disease or other severe concurrent disease
Other serious or life-threatening conditions deemed unacceptable by the principal investigator
History of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatment
No active, second potentially life-threatening cancer
Evidence of immediate life-threatening disease or a life expectancy of less than  months
Uncontrolled active life-threatening infection.
Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome
Known intolerance to or life threatening side effects resulting from prior checkpoint inhibitor therapy
Active life-threatening infection
Life-threatening visceral disease or other severe concurrent disease
Patient has malignancy or life-threatening systemic disease or a history of advanced, serious, life-threatening malignancy/disease within the last  years, except very low-risk prostate cancer
Active life-threatening infection
Has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the subject is to be disease free for at least  years. Subjects with other prior malignancies less than  years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. Subjects will not be excluded for recurrent NMIBC, basal or squamous cell skin cancers, or noninvasive cancer of the cervix.
Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeon
Active life-threatening infection
Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate
Patients with significant autoimmune disease that is active or potentially life threatening if activated
Has an uncontrolled, life-threatening active infection
No clinical evidence of life-threatening infection
Patients with untreated or uncontrolled life-threatening infection
Active life-threatening infection
Patients must not have untreated or uncontrolled life-threatening infection
No life threatening parenchymal disease or rapidly progressing disease warranting cytotoxic chemotherapy
Patients with advanced/metastatic, symptomatic, visceral spread, at risk of life-threatening complications in the short term by investigator assessment
Active life-threatening infection
Patients with a history of life-threatening autoimmune disease
Unstable or life-threatening arrhythmia
Active life-threatening infection
Significant extrahepatic disease representing an imminent life-threatening outcome
Active life-threatening cancer requiring treatment other than ALL
Active life-threatening autoimmune disease
MATCHED RELATED DONOR: No history of life-threatening opportunistic infection
HAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infection
Active life-threatening infection
Life-threatening visceral disease or other severe concurrent disease
No life- or organ-threatening manifestations of MCD
Active life-threatening infection
Severe life, threatening infection
Severe life, threatening infection
Significant extrahepatic disease representing an imminent life-threatening outcome
HAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infections
Active life-threatening infection
Significant extrahepatic disease representing an imminent life-threatening outcome
Significant extrahepatic disease representing an imminent life threatening outcome
Patients with an uncontrolled life-threatening infection
Advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening complications in the short term.
Patients with life-threatening condition or complication other than their basic condition
Known life-threatening systemic disease
Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of  months or less (eg, moribund or with shock unresponsive to fluid replacement)
Life-threatening visceral disease or other severe concurrent disease
Unstable or life-threatening arrhythmia
Life-threatening visceral disease or other severe concurrent disease
Life-threatening, visceral metastases
Presence of any life-threatening co-morbidity
Presence of any life-threatening co-morbidity
Patients with immediately life-threatening visceral disease, for whom chemotherapy is the preferred treatment option.
Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome
An active, second potentially life-threatening cancer
Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
Active life-threatening infection
Subjects with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term including subjects with massive uncontrolled effusions, pulmonary lymphangitis, and over % of liver involvement in metastases.
Immediately life-threatening, severe complications of leukemia.
Patient has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the patient is to be disease free for at least  years. Patients with other prior malignancies less than  years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease.
Patients must not have untreated or uncontrolled life-threatening infection
Patients with significant autoimmune disease that is active or potentially life threatening if activated
Participants must not have life-threatening co-morbidities
Patients with a history of life-threatening autoimmune disease
Active life-threatening infection
Life-threatening visceral disease or other severe concurrent disease
Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons, Allan Friedman, John Sampson, or Peter Fecci, or their designate, will be excluded
Any subject who has a life-threatening condition that requires high-dose immunosuppressant(s)
Extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or disease that is considered by the investigator to be rapidly progressing or life threatening (eg, subjects who are intended for chemotherapy)
Other serious or life-threatening conditions deemed unacceptable by the principal investigator
Rapidly progressive, symptomatic, visceral spread of disease placing participant at risk of life-threatening complications in the short term
Patients must not have untreated or uncontrolled life-threatening infection
History of life threatening or recurrent thrombosis/embolism; subjects may participate if they are adequately anticoagulated during the treatment
No untreated or uncontrolled life-threatening infection
Severe or life-threatening infection within  weeks of entry onto the study
Patients with an uncontrolled life-threatening infection
Life-threatening visceral disease or other severe concurrent disease
Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of  months or less.
Uncontrolled life-threatening infections
Any life-threatening condition that could affect protocol compliance.
Subject has an active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment.
Life-threatening visceral disease or other severe concurrent disease
Disease that is considered by the investigator to be rapidly progressing or life threatening such as extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumour (subjects who are intended for urgent chemotherapy)
Evidence of life-threatening or fulminant CDAD.
Serious and potentially life-threatening arrhythmia.
Patients must have had no prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than  cycle of chemotherapy per low- or intermediate-risk neuroblastoma therapy (P, A, ANBL) prior to determination of MYCN amplification and histology
Life-threatening, visceral metastases
History of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatment
Subjects must be free of life-threatening illness (e.g., cancer) that would severely limit participation; those with chronic illnesses (e.g., asthma, diabetes) may participate with the permission of their physician
Patients with immediately life-threatening visceral disease for whom chemotherapy is preferred treatment option.
Have current or a history of ventricular or life-threatening arrhythmias or diagnosis
Current metabolic or life-threatening disease
life threatening allergic reaction to food and/or drugs
Untreatable life-threatening arrhythmias
Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example:
Acute life threatening infection
Life-threatening metastatic visceral disease (defined as extensive hepatic involvement or symptomatic pulmonary lymphangitic spread).